Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).
The aim of our study was to elucidate the impact of bevacizumab added to neoadjuvant chemotherapy (NACT) on the tumor immune microenvironment and correlate the changes with the clinical outcome of the patients.
| Autores: | , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Institut d'Investigació i Innovació Parc Taulí (I3PT) |
| Repositorio: | r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí |
| OAI Identifier: | oai:i3pt.fundanetsuite.com:p4328 |
| Acceso en línea: | https://i3pt.portalinvestigacion.com/publicaciones/4328 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85181761067&doi=10.1158%2f1078-0432.CCR-23-0771&partnerID=40&md5=a4ac2303bc43a6a87bd90d23c549a28a |
| Access Level: | acceso abierto |
| Palabra clave: | Bevacizumab Carcinoma, Ovarian Epithelial Chemotherapy, Adjuvant Female Forkhead Transcription Factors Humans Neoadjuvant Therapy Ovarian Neoplasms Tumor Microenvironment bevacizumab carboplatin paclitaxel transcription factor FOXP3 forkhead transcription factor advanced cancer Article cancer resistance cancer survival CD4+ T lymphocyte CD8+ T lymphocyte cell subpopulation clinical article clinical outcome controlled study cytoreductive surgery female human human cell human tissue immunofluorescence immunohistochemistry multiple cycle treatment neoadjuvant chemotherapy ovary cancer progression free survival regulatory T lymphocyte tumor microenvironment tumor-associated macrophage adjuvant chemotherapy neoadjuvant therapy ovary carcinoma ovary tumor pathology procedures |
| Sumario: | The aim of our study was to elucidate the impact of bevacizumab added to neoadjuvant chemotherapy (NACT) on the tumor immune microenvironment and correlate the changes with the clinical outcome of the patients. |
|---|